Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been known. METHODS: In this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe coronavirus disease 2019 (Covid-19) 15 days or more after the second dose in adults, including older adults, in the United States, Chile, and Peru. RESULTS: A total of 32,451 participants underwent randomization, in a 2:1 ratio, to receive AZD1222 (21,635 participants) or placebo (10,816 participants). AZD1222 was safe, with low incidences of serious and medically attended adverse events and adverse events of special interest; the incidences were similar to those observed in the placebo group. Solicited local and systemic reactions were generally mild or moderate in both groups. Overall estimated vaccine efficacy was 74.0% (95% confidence interval [CI], 65.3 to 80.5; P<0.001) and estimated vaccine efficacy was 83.5% (95% CI, 54.2 to 94.1) in participants 65 years of age or older. High vaccine efficacy was consistent across a range of demographic subgroups. In the fully vaccinated analysis subgroup, no severe or critical symptomatic Covid-19 cases were observed among the 17,662 participants in the AZD1222 group; 8 cases were noted among the 8550 participants in the placebo group (<0.1%). The estimated vaccine efficacy for preventing SARS-CoV-2 infection (nucleocapsid antibody seroconversion) was 64.3% (95% CI, 56.1 to 71.0; P<0.001). SARS-CoV-2 spike protein binding and neutralizing antibodies increased after the first dose and increased further when measured 28 days after the second dose. CONCLUSIONS: AZD1222 was safe and efficacious in preventing symptomatic and severe Covid-19 across diverse populations that included older adults. (Funded by AstraZeneca and others; ClinicalTrials.gov number, NCT04516746.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Modified Poisson Regression Approach to Prospective Studies with Binary Data
Zou, G. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh090 · Cited by 9,615
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Schultz, N. H., Sørvoll, I. H., Michelsen, A. E., Munthe, L. A., Lund-Johansen, F., Ahlen, M. T., Wiedmann, M., Aamodt, A.-H., Skattør, T. H., Tjønnfjord, G. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104882 · Cited by 1,452
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324
Self-citationEfficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257
Self-citationMadhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · doi:10.1101/2021.02.10.21251247 · Cited by 1,257
Self-citationVoysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119
Self-citation
Research works printed but not linked: 1
- COVID-19 Vaccine Tracker. Oxford/AstraZeneca: AZD1222. 2021 (https://covid19.trackvaccines.org/vaccines/4/).
Cited by
Items 101–200 of 670
Bouazzaoui, A., & Abdellatif, A. A. H. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100500 · Cited by 44
“In a phase 3 study, the overall estimated efficacy reached 74.0 %, with low appearance of serious adverse events [68].”
BackgroundInfluentialSun, B., Wang, Q., Zheng, P., Niu, X., Feng, Y., Guan, W., Chen, S., Li, J., Cui, T., Deng, Y., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.180784 · Cited by 36
“All participants were monitored for infection by antigen tests, disease symptoms, and the elevation of nucleocapsid-specific sIgA in the nasal passage.”
BackgroundHertel, M., Schmidt‐Westhausen, A. M., Wendy, S., Heiland, M., Nahles, S., Preißner, R., & Preißner, S. (2022) · Vaccines · doi:10.3390/vaccines10030480 · Cited by 31
Martellucci, C. A., Flacco, M. E., Soldato, G., Martino, G. D., Carota, R., Caponetti, A., & Manzoli, L. (2022) · Vaccines · doi:10.3390/vaccines10050662 · Cited by 34
Immunizing the imperfect immune system
Durkee-Shock, J., & Keller, M. (2022) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2022.06.009 · Cited by 20
“Similarly, ArroyoSanchez et al evaluated 18 patients with CVID, including 1 patient who received ChAdOX1-S.(43,67) Although 83% of patients with CVID also have an anti-spike T cell response, the magnitude of both antibody and cellular responses in CVID was lower than HC.”
MethodInnate and adaptive immunity to SARS-CoV-2 and predisposing factors
Shen, J., Fan, J., Zhao, Y., Jiang, D., Niu, Z., Zhang, Z., & Cao, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1159326 · Cited by 44
Biosafety assessment of delivery systems for clinical nucleic acid therapeutics
Li, Z., Zhang, L., Jiang, K., Zhang, Y., Liu, Y., Hu, G., & Song, J. (2022) · Biosafety and Health · doi:10.1016/j.bsheal.2022.03.003 · Cited by 32
Sandoval, C., Guerrero, D., Muñoz, J., Godoy, K., Souza‐Mello, V., & Farías, J. G. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2156861 · Cited by 31
“In fact, although high neutralizing titers were attained 14 days following the booster immunization in participants between 18 or older [39,40]; a non-neutralizing level was found in the LD/LD group in participants aged 70 and older [40].”
BackgroundMethodInfluentialGenetic determinants of IgG antibody response to COVID-19 vaccination
Bian, S., Guo, X., Yang, X., Wei, Y., Yang, Z., Cheng, S., Yan, J., Chen, Y., Chen, G., Du, X., et al. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.12.005 · Cited by 34
“51,52 We found a consistent pattern wherein the frequency of HLA-DRB1*13:02 progressively decreased across the African, European, and Asian ancestry groups, registering values of 7.34%, 4.85%, and 2.40%, respectively (Table S22).”
BackgroundInfluentialGlobal COVID-19 vaccination challenges: Inequity of access and vaccine hesitancy
Dagovetz, M., Momchilov, K., Blank, L., Khorsandi, J., Rizzo, A., Khabbache, H., Sitibondo, A., Gómez-Salgado, J. C., Chirico, F., & Batra, K. (2025) · Journal of Medicine Surgery and Public Health · doi:10.1016/j.glmedi.2025.100197 · Cited by 39
Kwok, W. C., Leung, I. S. H., Tam, T. C. C., Ho, J., Lam, D. C.-L., Ip, M., & Ho, P. (2023) · International Journal of COPD · doi:10.2147/copd.s394101 · Cited by 29
Grant, M. D., Bentley, K., Fielding, C. A., Hatfield, K. M., Ings, D. P., Harnum, D. O. A., Wang, E. C. Y., Stanton, R. J., & Holder, K. A. (2023) · JCI Insight · doi:10.1172/jci.insight.170681 · Cited by 31
Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV
Matveev, V., Mihelic, E. Z., Benko, E., Budylowski, P., Grocott, S., Lee, T., Korosec, C. S., Colwill, K., Stephenson, H., Law, R., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107915 · Cited by 28
“Older agewas also associatedwith lower T cell responses for ChAdOx1, but the efficacy was not affected.(21,22) Studies on PWH inCOVID-19 vaccine trials were limited,(23,25) but they showed strong initial immune responses after two vaccine doses.”
Clinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A. P., Kachanov, A., Brezgin, S. A., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 31
Chansaenroj, J., Suntronwong, N., Kanokudom, S., Assawakosri, S., Yorsaeng, R., Vichaiwattana, P., Klinfueng, S., Wongsrisang, L., Srimuan, D., Thatsanatorn, T., et al. (2022) · Vaccines · doi:10.3390/vaccines10071071 · Cited by 27
“5 mL) contains 5 × 1010 infectious units [23].”
May, D., Rubin, B. E., Dalai, S. C., Patel, K. J., Shafiani, S., Elyanow, R., Noakes, M. T., Snyder, T. M., & Robins, H. S. (2021) · medRxiv · doi:10.1101/2021.12.20.21267877 · Cited by 30
Hahn, W. O., & Wiley, Z. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.01.008 · Cited by 29
Self-citationActive Safety Surveillance of Four Types of COVID-19 Vaccines: A National Study from Jordan
Abdel‐Qader, D. H., Abdel-Qader, H., Silverthorne, J., Kongkaew, C., Meslamani, A. Z. A., Hayajneh, W. A., Ata, O. A., Shnaigat, W., Aburuz, S., Nsour, M. A., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01191-1 · Cited by 25
Lu, M., Yao, Y., Liu, H., Zhang, X., Li, X., Liu, Y., Peng, Y., Chen, T., Sun, Y., Gao, G., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.175461 · Cited by 24
Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis
Wu, X., Xu, K., Zhan, P., Liu, H., Zhang, F., Song, Y., & Lv, T. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-023-08754-3 · Cited by 29
Debbag, R., Rudin, D., Ceddia, F., & Watkins, J. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01079-x · Cited by 32
Impact of prior vaccination on clinical outcomes of patients with COVID-19
Seo, W. J., Kang, J., Kang, H. K., Park, S. H., Koo, H., Park, H. K., Lee, S.-S., Song, J. E., Kwak, Y. G., & Kang, J. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2069516 · Cited by 24
“Following the demonstration of effective prevention of COVID-19 by several vaccines in phase-3 trials, they have been approved [8-11].”
BackgroundInfluentialWilkins, D. E., Aksyuk, A. A., Ruzin, A. V., Tuffy, K. M., Green, T., Greway, R., Fikes, B., Bonhomme, C. J., Esser, M. T., & Kelly, E. J. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1385 · Cited by 23
Self-citationIndividual-level social capital and COVID-19 vaccine hesitancy in Japan: a cross-sectional study
Machida, M., Kikuchi, H., Kojima, T., Nakamura, I., Saito, R., Nakaya, T., Hanibuchi, T., Takamiya, T., Odagiri, Y., Fukushima, N., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2086773 · Cited by 23
Reynolds, L., Dewey, C. E., Asfour, G., & Little, M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1229716 · Cited by 26
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Zhu, C., Pang, S., Liu, J., & Duan, Q. (2024) · Drugs · doi:10.1007/s40265-024-02013-8 · Cited by 28
“However, the level of neutralizing antibodies induced by mRNA-based vaccines starts to decline after 3–6 months and drops further after 8 months, with a half-life of approximately 2 months [103–107].”
T-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination
Notarbartolo, S. (2024) · Vaccines · doi:10.3390/vaccines12101126 · Cited by 23
“According to the results from phase III clinical trials, the protection against the wild-type SARS-CoV-2-induced disease ranges from 94 to 95% of two doses of mRNA-based vaccines [124,125] to 67–74% of one or two doses of adenoviral vector-based vaccines [126,127].”
Karbiener, M., Farcet, M. R., Zollner, A., Masuda, T., Mori, M., Moschen, A. R., & Kreil, T. R. (2022) · npj Vaccines · doi:10.1038/s41541-022-00455-3 · Cited by 20
Vaccine versus infection – COVID-19-related loss of training time in elite athletes
Krzywański, J., Mikulski, T., Krysztofiak, H., Pokrywka, A., Sobierajski, T., Młyńczak, M., Piechuta, A., & Kuchar, E. P. (2022) · Journal of science and medicine in sport · doi:10.1016/j.jsams.2022.10.004 · Cited by 24
Kerr, S., Bedston, S., Bradley, D., Joy, M., Lowthian, E., Mulholland, R., Akbari, A., Hobbs, R. F., Katikireddi, S. V., de Lusignan, S., et al. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac199 · Cited by 24
“Clinical trials for both ChAdOx1 and BNT162b2 reported 100% efficacy against severe COVID-19 outcomes after a two-dose regimen.(5,6) There are several possible explanations for this.”
Kumar, S., Saikia, D., Bankar, M., Saurabh, M. K., Singh, H., Varikasuvu, S. R., & Maharshi, V. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00429-1 · Cited by 26
Chang, Y., Lv, G., Liu, C., Huang, E., & Luo, B. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2150169 · Cited by 24
“Moreover, several large studies have evaluated that clinical trials of the COVID-19 vaccine have demonstrated a good safety([2]) and efficiency([3]), and that full vaccination is effective in preventing the incidence of severe illness and mortality after COVID-19 infection.”
BackgroundAl-Sheboul, S. A., Brown, B., Shboul, Y., Fricke, I., Imarogbe, C., & Alzoubi, K. H. (2022) · Vaccines · doi:10.3390/vaccines11010051 · Cited by 25
SARS-CoV-2 infection and immune responses
Harne, R., Williams, B., Abdelaal, H. F. M., Baldwin, S. L., & Coler, R. N. (2023) · AIMS Microbiology · doi:10.3934/microbiol.2023015 · Cited by 24
Theodore, D., Branche, A. R., Zhang, L., Graciaa, D. S., Choudhary, M., Hatlen, T. J., Osman, R., Babu, T. M., Robinson, S. T., Gilbert, P. B., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.23349 · Cited by 31
Self-citationBabu, T. M., Feldstein, L. R., Saydah, S., Acker, Z., Boisvert, C. L., Briggs‐Hagen, M., Carone, M., Casto, A. M., Cox, S. N., Ehmen, B., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-071446 · Cited by 26
Gao, Y., Wang, W., Yang, Y., Zhao, Q., Yang, C., Jia, X., Liu, Y., Zhou, M., Zeng, W., Huang, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202204598 · Cited by 25
Gemmati, D., Longo, G., Gallo, I., Silva, J. A., Secchiero, P., Zauli, G., Hanau, S., Passaro, A., Pellegatti, P., Pizzicotti, S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1028081 · Cited by 24
“, Pfizer–BioNTech or Moderna), potentially offering similar efficacy and safety (Falsey et al., 2021; Thomas et al., 2021).”
BackgroundAksyuk, A. A., Bansal, H., Wilkins, D. E., Stanley, A. M., Sproule, S., Maaske, J., Sanikommui, S., Hartman, W. R., Sobieszczyk, M. E., Falsey, A. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100882 · Cited by 25
“71 Pseudovirus neutralization assay As outlined in (Falsey et al. 2021; Sobieszczyk et al. 2022), 3,64 neutralizing antibodies in sera were assessed in a validated lentivirus-based SARS-CoV-2 pseudovirus assay (Monogram Biosciences, South San Francisco, CA).”
Self-citationEncephalitis following COVID-19 Vaccination: A Systematic Review
Abdelhady, M., Husain, M. A., Hawas, Y., Elazb, M., Mansour, L. S., Mohamed, M., Abdelwahab, M. M., Aljabali, A. S., & Negida, A. (2023) · Vaccines · doi:10.3390/vaccines11030576 · Cited by 24
“Nonetheless, no encephalitis-associated symptoms were reported [34].”
Living with HIV and Getting Vaccinated: A Narrative Review
VITO, A. D., Colpani, A., Trunfio, M., Fiore, V., Moi, G., Fois, M., Leoni, N., Ruiu, S., Babudieri, S., Calcagno, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11050896 · Cited by 23
Developing the next-generation of adenoviral vector vaccines
Sampson, A., Hlaváč, M., Gillman, A. C. T., Douradinha, B. G., & Gilbert, S. C. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2514356 · Cited by 30
Infection by SARS‐CoV‐2 with alternate frequencies of mRNA vaccine boosting
Townsend, J. P., Hassler, H. B., & Dornburg, A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28461 · Cited by 25
Autoimmune liver diseases and SARS-CoV-2
Sgamato, C., Rocco, A., Compare, D., Minieri, S., Marchitto, S. A., Maurea, S., & Nardone, G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i12.1838 · Cited by 26
Marchese, A. M., Rousculp, M. D., Macbeth, J. C., Beyhaghi, H., Seet, B. T., & Toback, S. L. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad519 · Cited by 21
Current Advances in Viral Nanoparticles for Biomedicine
Sun, X., Tian, T., Lian, Y., & Cui, Z. (2024) · ACS Nano · doi:10.1021/acsnano.4c13146 · Cited by 21
Antibody response to COVID-19 vaccination in patients with lymphoma
Narita, K., Nakaji, S., Tabata, R., Terao, T., Kuzume, A., Tsushima, T., Ikeda, D., Fukumoto, A., Miura, D., Takeuchi, M., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03305-z · Cited by 20
Sobczak, M., & Pawliczak, R. (2022) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-022-00525-3 · Cited by 20
“Two studies were conducted in South Africa [22, 26], one study in South Africa, Brazil, and the United Kingdom [25], one study in Indonesia [29], one study in Russia [20], one study in Brazil [23], one in the United Kingdom [27], one in Turkey [30], one in the United States, Chile, and Peru [24], one in South Africa,…”
BackgroundHuang, W., Chiem, K., Martínez‐Sobrido, L., & Lovell, J. F. (2022) · Pathogens · doi:10.3390/pathogens11091035 · Cited by 20
Crombé, A., Bensid, L., Seux, M., Fadli, D., Arnaud, F., Benhamed, A., Banaste, N., & Gorincour, G. (2023) · Radiology · doi:10.1148/radiol.222730 · Cited by 19
“Absent 155/1037 (15) 504/1465 (34) Present 882/1037 (85) 961/1465 (66) .”
The effect of HIV on COVID-19 vaccine responses
Levy, I., & Rahav, G. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000790 · Cited by 23
Park, W. B., Hwang, Y. H., & Cheong, H. J. (2023) · Infection and Chemotherapy · doi:10.3947/ic.2023.0023 · Cited by 19
Inkjet printing-based high-throughput DNA synthesis
Deng, X. J., Li, H., & Song, Y. (2023) · Giant · doi:10.1016/j.giant.2023.100222 · Cited by 23
Vaccines for the Elderly and Vaccination Programs in Europe and the United States
Anastassopoulou, C. G., Ferous, S., Medić, S., Siafakas, N., Boufidou, F., Gioula, G., & Tsakris, A. (2024) · Vaccines · doi:10.3390/vaccines12060566 · Cited by 24
“However, the incidence of SARS-CoV-2 infections in the over-65 age group was 0.1% in the vaccine arm and 0.8% in the placebo arm, compared to 0.5% in the vaccine arm and 1.7% in the placebo arm of the 18 to 64 age group [177].”
BackgroundInfluentialLovell, J. F., Miura, K., Baik, Y. O., Lee, C., Choi, Y., Her, H., Lee, J., Ylade, M. C., Lee‐Llacer, R., Asis, N. D., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29927 · Cited by 20
Xu, Y., Li, H., Kirui, B. K., Santosa, A., Gisslén, M., Leach, S., Wettermark, B., Vanfleteren, L. E. G. W., & Nyberg, F. (2022) · Vaccines · doi:10.3390/vaccines10122074 · Cited by 19
Wong, T. Y., Horspool, A. M., Russ, B. P., Ye, C., Lee, K. S., Winters, M. T., Bevere, J. R., Miller, O. A., Rader, N. A., Cooper, M., et al. (2022) · Journal of Virology · doi:10.1128/jvi.02184-21 · Cited by 17
Lee, M., & Kim, B. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-1621-2 · Cited by 19
“Among the 5 vaccines approved for emergency use, AZD1222 (ChAdOx1 nCoV-19, NCT04516746, NCT04760132) is based on a chimpanzee adenovirus vector that contains the SARS-CoV-2 spike protein (Table 2).”
BackgroundInfluentialShao, Y., Wu, Y., Feng, Y., Xu, W., Xiong, F., & Zhang, X. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0913-y · Cited by 23
Flitter, B. A., Braun, M. R., & Tucker, S. N. (2022) · Vaccines · doi:10.3390/vaccines10040593 · Cited by 20
Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity
Ford, B. N., & Savitz, J. B. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00288-7 · Cited by 19
Assawakosri, S., Kanokudom, S., Chansaenroj, J., Suntronwong, N., Auphimai, C., Nilyanimit, P., Vichaiwattana, P., Thongmee, T., Duangchinda, T., Chantima, W., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.07.038 · Cited by 17
Population-Wide Persistent Hemostatic Changes After Vaccination With ChAdOx1-S
de Laat, B., Stragier, H., Kremers, R., Ninivaggi, M., Mesotten, D., Thiessen, S., Pelt, K. V., Roest, M., Penders, J., Vanelderen, P., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.966028 · Cited by 18
Ferreira, L. S., de Almeida, G. B., Borges, M. E., Simon, L. M., Poloni, S., Bagattini, Â. M., da Rosa, M. Q. M., Diniz‐Filho, J. A. F., Kuchenbecker, R. D. S., Camey, S. A., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.082 · Cited by 19
A community-partnered approach for diversity in COVID-19 vaccine clinical trials
Castellon‐Lopez, Y., Landovitz, R. J., Ntekume, E., Porter, C. L., Bross, R., Hilder, R., Lucas‐Wright, A., Daar, E. S., Chavez, P. I., Blades, C., et al. (2022) · Journal of Clinical and Translational Science · doi:10.1017/cts.2022.471 · Cited by 24
Self-citationFernández-Ciriza, L., González, Á., del Pozo, J. L., Fernández‐Montero, A., Carmona-Torre, F., Carlos, S., Sarasa, M. D. M., & Reina, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-19537-2 · Cited by 22
A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants
Rabaan, A. A., Mutair, A. S. A., Hajissa, K., Alfaraj, A. H., Al-Jishi, J. M., Alhajri, M. M., Alwarthan, S. M., Alsuliman, S. A., Al-Najjar, A. H., Al-Zaydani, I. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10101655 · Cited by 18
“6) after 14 days of receiving the second dose [81,82].”
BackgroundRisk of COVID-19 after natural infection or vaccination
Rick, A.-M., Laurens, M. B., Huang, Y., Yu, C., Martin, T., Rodriguez, C. A., Rostad, C. A., Maboa, R., Baden, L. R., Sahly, H. M. E., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104799 · Cited by 22
Self-citationFactors Predicting COVID-19 Vaccine Effectiveness and Longevity of Humoral Immune Responses
Berber, E., & Ross, T. M. (2024) · Vaccines · doi:10.3390/vaccines12111284 · Cited by 23
The current status of COVID-19 vaccines. A scoping review
Rueda-Fernández, M., Melguizo‐Rodríguez, L., Costela-Ruiz, V. J., González‐Acedo, A., Ramos‐Torrecillas, J., & Montes, R. I. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.08.004 · Cited by 21
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
Marchevsky, N. G., Li, G., Aley, P., Costa Clemens, S. A., Barrett, J. R., Belij-Rammerstorfer, S., Bibi, S., Clutterbuck, E., Dold, C., Felle, S., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104128 · Cited by 17
Cohen, G., Jungsomsri, P., Sangwongwanich, J., Tawinprai, K., Siripongboonsitti, T., Porntharukchareon, T., Wittayasak, K., Thonwirak, N., Soonklang, K., Sornsamdang, G., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2052525 · Cited by 17
Accelerating clinical trial development in vaccinology: COVID-19 and beyond
Corey, L., & Miner, M. D. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102206 · Cited by 18
Self-citationNaseem‐Khan, S., Berger, M. B., Leddin, E. M., Maghsoud, Y., & Cisneros, G. A. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00201 · Cited by 18
O’Connor, M. A., Hawman, D. W., Meade-White, K. D., Leventhal, S. S., Song, W., Randall, S., Archer, J. F., Lewis, T. B., Brown, B., Fredericks, M., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011298 · Cited by 19
“PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1011298 April 19, 2023 15 / 24 Notably, following phase II/III trials evaluating the safety, immunogenicity and non-inferiority of this vaccine at a 10 μg dose compared to the licensed adenovirus-based COVID-19 vaccine, COVISHIELD (LINK)[47], this vaccine received…”
BackgroundInfluentialLoosen, S. H., Bohlken, J., Weber, K., Konrad, M., Luedde, T., Roderburg, C., & Kostev, K. (2022) · Vaccines · doi:10.3390/vaccines10040566 · Cited by 16
Park, S., & Suh, Y. (2023) · Journal of Medical Internet Research · doi:10.2196/42623 · Cited by 16
Utilization of Viral Vector Vaccines in Preparing for Future Pandemics
Hofmeyer, K. A., Bianchi, K. M., & Wolfe, D. (2022) · Vaccines · doi:10.3390/vaccines10030436 · Cited by 17
“0% at 15 or more days after the second dose [91].”
BackgroundTan, J. S., Ali, M. N. B. J., Gan, B. K., & Tan, W. S. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2228202 · Cited by 17
Mohraz, M., Vahdat, K., Ghamari, S., Abbasi‐Kangevari, M., Ghasemi, E., Ghabdian, Y., Rezaei, N., Pouya, M. A., Abdoli, A., Malekpour, M., et al. (2023) · BMJ · doi:10.1136/bmj-2023-070464 · Cited by 16
Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer
Body, A. L., Lal, L., Srihari, S., MacIntyre, C. R., Buttery, J. P., Ahern, E. S., Opat, S., Leahy, M. F., Hamad, N., Milch, V., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126547 · Cited by 18
Case report of acute encephalitis following the AstraZeneca COVID‐19 vaccine
Li, S., Chen, H., Liu, P., Shi, Z., Lin, Y., Tsai, C.-A., & Lin, S. (2022) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14372 · Cited by 15
Wang, C., Chen, C., Lu, C., Chen, W., Hui, R. C., Chiu, T., Chi, M., Lin, J.-C., Huang, Y., Chang, Y., et al. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103054 · Cited by 17
The Effect of Vaccine Mandates on Disease Spread: Evidence from College COVID-19 Mandates
Acton, R. K., Cao, W., Cook, E., Imberman, S. A., & Lovenheim, M. (2022) · National Bureau of Economic Research · doi:10.3386/w30303 · Cited by 17
“…demonstrated that vaccines approved by the US Food and Drug Administration (FDA) help protect people from being infected with the SARS-CoV-2 virus, and, conditional on being infected, reduce the likelihood of hospitalization and death (Polack et al. 2020; Baden et al. 2021; Falsey et al. 2021).”
Fitting the reproduction number from UK coronavirus case data and why it is close to 1
Ackland, G. J., Ackland, J., Antonioletti, M., & Wallace, D. J. (2022) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2021.0301 · Cited by 13
Widyasari, K., Jang, J., Lee, S. J., Kang, T., & Kim, S. (2022) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2022.09.004 · Cited by 15
Beyond COVID-19: the promise of next-generation coronavirus vaccines
Mukesh, R. K., Yinda, C. K., Munster, V. J., & van Doremalen, N. (2024) · npj Viruses · doi:10.1038/s44298-024-00043-3 · Cited by 17
Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies
Muthukutty, P., MacDonald, J., & Yoo, S. Y. (2024) · Vaccines · doi:10.3390/vaccines12111220 · Cited by 20
“…aged 65 and older and was carried out in the United States, Peru, and Chile, found that individuals who received two doses of the vaccine (with the second dose administered four weeks after the first) had a 74% lower incidence of symptomatic COVID-19 compared to the control group [234,235].”
Susac Syndrome Following COVID-19 Vaccination: A Case Report
Chen, P.-J., Chang, Y.-S., Lim, C.-C., & Lee, Y.-K. (2022) · Vaccines · doi:10.3390/vaccines10030363 · Cited by 15
“The novel ChAdOx1 vaccine, an adenoviral vector vaccine using a replication-incompetent adenovirus as a vector to deliver the DNA signal sequence of the spike protein, is one of the most commonly used COVID-19 vaccines worldwide [11].”
MethodLow-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity
Liao, H., Wu, W.-L., Chiang, C.-Y., Huang, M., Shen, K., Huang, Y., Wu, S., Liao, C., Chen, H., & Liu, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094902 · Cited by 15
Skarzynska, M. B., Matusiak, M., & Skarzynski, P. H. (2022) · Audiology Research · doi:10.3390/audiolres12030025 · Cited by 15
“Name of Medication: Anti-COVID-19 Treatment (Monoclonal Antibodies, Anti-Inflammatory Treatment) Population Route of Administration Dose and Dosage Ototoxicity as an Adverse Reaction and the Source of Information Clinical Trial Information Tixagevimab and Cilgavimab The pre-exposure prophylaxis of coronavirus disease…”
BackgroundResultInfluentialIncidence and management of the main serious adverse events reported after COVID ‐19 vaccination
Padilla‐Flores, T., Sampieri, A., & Vaca, L. A. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1224 · Cited by 20
Serious harms of the COVID-19 vaccines: a systematic reviewPreprint
Gøtzsche, P. C., & Demasi, M. (2022) · medRxiv · doi:10.1101/2022.12.06.22283145 · Cited by 19
Efficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction
Marabotti, C. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2067531 · Cited by 13
“1 81 (Moderna-NIH) ChAdOx1nCoV19 [5] 1.”
Sherman, A. C., Gray, G., Cao, B., To, K. K., Rouphael, N., Restrepo, A. M. H., Gordon, A. C., & Baden, L. R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00662-x · Cited by 23
Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19
Yegiazaryan, A., Abnousian, A., Alexander, L. J., Badaoui, A., Flaig, B., Sheren, N., Aghazarian, A., Alsaigh, D., Amin, A., Mundra, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169297 · Cited by 14
“7% efficacy against SARS-CoV-2, while ChAdOx1nCoV-19 is two doses giving a 74% efficacy against the virus [117,118].”
BackgroundIto, Y., Honda, A., & Kurokawa, M. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.03.012 · Cited by 15
Levi, N., Moravsky, G., Weitsman, T., Amsalem, I., Itach, S. B., Algur, N., Lapidus, I., Mitz, O., Glikson, M., Weil‐Weiner, Y., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2687 · Cited by 14
Maaske, J., Sproule, S., Falsey, A. R., Sobieszczyk, M. E., Luetkemeyer, A. F., Paulsen, G. C., Riddler, S. A., Robb, M. L., Rolle, C.-P., Sha, B. E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1062067 · Cited by 17
“Median ILL-D1 nAb titers were comparable to peak titers observed 28 days after dose 2 of AZD1222 (13) and further increased throughout the illness visit period, with higher titers in vaccinees than in placebo recipients at all time points (Figure 3B).”
BackgroundMethodResultInfluentialSelf-citationVoysey, M., Flaxman, A. L., Aboagye, J., Aley, P. K., Belij‐Rammerstorfer, S., Bibi, S., Bittaye, M., Cappuccini, F., Charlton, S., Clutterbuck, E., et al. (2023) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad013 · Cited by 16
“5%) [1, 2] Data continue to accrue demonstrating that vaccination against COVID-19 prevents hospitalization and death with positive outcomes demonstrated after vaccination with a single dose of ChAdOx1 nCoV-19 [2–4].”
Background
Metadata
- Authors
- Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., Neuzil, K. M., Hahn, W., Hunt, J., Mulligan, M. J., McEvoy, C., DeJesus, E., Hassman, M., Little, S. J., Pahud, B. A., Durbin, A., Pickrell, P., Daar, E. S., Bush, L., Solis, J., Carr, Q. O., Oyedele, T., Buchbinder, S., Cowden, J., Vargas, S. L., Guerreros Benavides, A., Call, R., Keefer, M. C., Kirkpatrick, B. D., Pullman, J., Tong, T., Brewinski Isaacs, M., Benkeser, D., Janes, H. E., Nason, M. C., Green, J. A., Kelly, E. J., Maaske, J., Mueller, N., Shoemaker, K., Takas, T., Marshall, R. P., Pangalos, M. N., Villafana, T., & Gonzalez-Lopez, A.
- Affiliations
- Columbia University Irving Medical Center (US)
- From the University of Rochester School of Medicine and Dentistry (A.R.F., M.C.K.) and Rochester Regional Health (A.R.F.), Rochester, and Vagelos College of Physicians and Surgeons, New York Presbyterian Columbia University Irving Medical Center, Department of Medicine, Division of Infectious Diseases (M.E.S.) and the New York University Vaccine Center (M.J.M.), New York — all in New York; Biometrics (I.H.) and Infectious Diseases (J.A.G.), Late-Stage Development, Respiratory and Immunology (R.P.M.), Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, United Kingdom; Biometrics (S.S., K.S.) and Infectious Diseases, Late-Stage Development, Respiratory and Immunology (J.M., T. Takas, T.V., A.G.-L.), Translational Medicine, Microbial Sciences, Biopharmaceuticals Research and Development (E.J.K.), and Clinical Development, Early Global Development, Oncology Research and Development (N.M.), AstraZeneca, Gaithersburg, the Walter Reed Army Institute of Research, Silver Spring (M.L.R.), t...
- Corresponding author
- Villafana, Tonya
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-16
- Volume
- 385
- Issue
- 25
- Pages
- 2348-2360
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8522798
- OpenAlex
- W3202234535
- Cited by
- 670
- References
- 21
- Citations by year
- 2026: 33 · 2025: 72 · 2024: 97 · 2023: 185 · 2022: 259 · 2021: 24
- FWCI
- 44.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- United States Government (Agreement No. W15QKN-20-9-1003)
- National Institute of Allergy and Infectious Diseases (UM1 AI 148372, UM1 AI 148450, UM1 AI 148574, UM1 AI 148684, UM1 AI 148684-03, UM1 AI 68614HVTN, UM1 AI 68618, UM1 AI 68619, UM1 AI 68635, UM1 AI 68636)
- Biomedical Advanced Research and Development Authority (W15QKN-21-9-1003)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- ChAdOx1 nCoV-19 vaccine, COVID-19 vaccines, SARS-CoV-2, vaccine efficacy, vaccine safety, immunogenicity, neutralizing antibodies, nucleocapsid antibodies, older adults, adverse events
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, Vaccine Efficacy, ChAdOx1 nCoV-19, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Chile, Double-Blind Method, Female, Humans, Male, Middle Aged, Peru, United States, Young Adult, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.